Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.

NCT01962922 is registered in ClinicalTrials.gov with Veloxis Pharmaceuticals as lead sponsor.

NCT NCT01962922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01962922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.
Lead sponsor
Veloxis Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2013
Completion date
August 31, 2015
Enrollment
50 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure